QIAGEN N.V. announced a strategic collaboration to develop tissue-based companion diagnostics for Amgen's investigational cancer treatment AMG 510 to identify patients with cancers that have the KRAS G12C mutation. The agreement focuses initially on companion diagnostics for non-small cell lung cancer (NSCLC) but allows for further development of the tests for Amgen's other oncology clinical development programs. The therascreen-based companion diagnostic will screen for KRAS G12C, a genetic mutation that is one of the most common causes of cancer. The RAS gene family, studied for almost 40 years, includes the most frequently mutated oncogenes in human cancers with KRAS being the most prevalent driver mutation in NSCLC.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.23 USD | -2.09% |
|
-4.28% | -10.15% |
06-27 | Wolfe Research Upgrades Qiagen to Outperform From Peer Perform, Price Target is $50 | MT |
06-21 | Qiagen Seeks M&A | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.15% | 8.92B | |
+16.59% | 44.44B | |
-9.89% | 37.99B | |
+38.08% | 37.75B | |
+27.12% | 30.78B | |
-8.64% | 27.38B | |
+11.81% | 26.17B | |
+45.08% | 14.15B | |
+32.85% | 12.59B | |
-7.19% | 11.28B |
- Stock Market
- Equities
- QGEN Stock
- News Qiagen N.V.
- QIAGEN N.V. Announces a Strategic Collaboration to Develop Tissue-Based Companion Diagnostics for Amgen’s Investigational Cancer Treatment AMG 510